Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genetic testing will "destroy" private health market:

This article was originally published in Clinica

Executive Summary

Genetic "fortune-telling" will obliterate the current system of private medical and life insurance within the next 30 to 50 years. This is the opinion of Sir Paul Nurse, the Nobel prize-winning scientist who jointly heads Cancer Research UK. In the UK, the government will introduce screening for diseases such as cancer and that predicting disease is incompatible with medical insurance, he told the UK newspaper, The Guardian. But many othersare not so convinced. Stephen Sklaroff, deputy director of the Association of British Insurers, believes that the number of conditions for which genetic test results would be relevant for insurance conditions are going to be "pretty small". Furthermore, there is definitely opposition to such a development among the insurance industry: in 1998, the insurance industry set up a code of practice agreeing not to demand genetic tests from individual seeking UK medical insurance. Such a policy, if it continues, may be the salvation of the private medical insurance industry.

You may also be interested in...

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts